Programs Advancing Toward the Clinic
Four active programs spanning oncology and inflammatory disease — each built on the Neologicals targeted delivery platform and advancing through a rigorous development pathway toward clinical proof-of-concept.
Neologicals-001 is a first-in-class EGFR-targeted conjugate designed for patients with advanced solid tumors harboring EGFR overexpression. The program has demonstrated 87% tumor volume reduction in EGFR+ xenograft models and is currently enrolling patients in a Phase I/II dose-escalation and expansion study.
- 87% tumor reduction in EGFR+ xenograft models
- Phase I/II dose-escalation study active
- Favorable tolerability profile in preclinical toxicology
- Biomarker-selected patient population
Development Stage Definitions
Target validation, ligand design, and lead optimization in cellular models
In vivo efficacy and safety studies in disease-relevant animal models
GLP toxicology, CMC development, and regulatory package preparation
First-in-human dose escalation and preliminary efficacy in selected patient populations
Pivotal efficacy and safety trials for regulatory approval
Partner on Our Pipeline
We are actively seeking co-development partners, licensing discussions, and strategic investors to accelerate our programs toward clinical milestones.